Dr Barbara Guinn

Trustee of EndoBuddies

2023 - 2024

EndoBuddies provides hundreds of care packages that have either been given out on Surgery days or posted to people in desperate need of a little bit of love and support. They are currently being handed out on Surgery days at the Endometriosis Specialist Centre at Castle Hill Hospital, Cedar ward at Hull Royal Infirmary, and we also post them out across the country too. It's thanks to every single person who has donated to the project that has made it possible for Katy Phillips's little idea to become a reality. Katy has a wishlist on Amazon if anyone would like to purchase anything to help make the care packages which are then given to patients. https://www.amazon.co.uk/hz/wishlist/ls/29CWYEN1SSJMA... Or, if anyone wants to donate funds please click the following link... https://gofund.me/bf48633b

Raising money for Endometriosis Research at the University of Hull

2021

In August 2021 I wrote 'I am a researcher at the University of Hull and we want to develop new ways to diagnose endometriosis earlier and better understand this awful disease. Although we continue to apply for grants to fund our research we need some help paying for equipment and chemicals that will progress our research now. That way we can generate data quickly, and help make a difference ASAP.' It's now December 2021 and we have brought in grants from EACR-Novosanis and British Society for Gynaecological Endoscopy to help pay for our lab consumables (plasticwear, test kits). Although this is helping us progress our research significantly we will continue to fund raise until we have a way to improve the ease of diagnosis and effectivity of treatment for endometriosis patients. If you would like to support us the link for donations is https://alumni.hull.ac.uk/donation-form-endometriosis

Cancer Research U.K. Ambassador

2007

Endometriosis Research Priority Setting

2025 - 2025

World Endometriosis Society (WES) and World Endometriosis Research Foundation (WERF) will hold the next Endometriosis Research Priority Setting Session (in-person) on May 25 2025 following the World Congress on Endometriosis (WCE2025) in Sydney. The previous iteration of the research priorities (https://pubmed.ncbi.nlm.nih.gov/27368878/) underwent revision at WCE2017. A literature review has been updated by WES Early Career Ambassadors, based on which the research priorities have been reworded and consolidated to a list of 55 priorities. Based on my experience/work in endometriosis, I and other experts in the field are rating these 55 priorities and these responses will be collated and used to will be collated and used to guide the discussions at the session on May 25 in Sydney.

Endometriosis UK Networking Group

2024

Member of the Endometriosis UK Networking Group which meets at least once a year to present data, exchange ideas, foster collaborations and share reagents. Attended meetings in Liverpool (2024) and Dundee (2025) to date.

PIVAC23: Session chair: Cancer Biomarkers for Prognosis and Prediction (Part II)

2023

Expert Reviewer for 25th Congress of the European Haematology Association

2020 - 2020

Session Chair at 6th Symposium on Advances in Cancer Immunotherapy: Tumor Immunology (I)

2020

Best Practise in Non-Animal Research Methods Conference Speaker, York, UK

2025 - 2025

Delivered a talk titled 'A cell line model of early ovarian cancer' at the Best Practise in non-Animal Research Methods Conference. Organised by Replacing Animal Research, The Humane Research Trust CIO and Centre for Human Specific Research this 2 day York-based conference showcased innovative animal replacement research with lively panel discussions and opportunities to view posters, sponsors/exhibitors and networking, including a reception and dinner.

Invited Speaker at the UK Endometriosis Network Meeting, Liverpool, UK

2024 - 2024

Invited Speaker at PIVAC23 in Athens, Greece

2023

Invited Speaker at “The 22nd International Conference on Progress in Vaccination Against Cancer” (PIVAC-23) which was held from 28th –30th September 2023 in Athens, Greece at the Saint Savvas Cancer Hospital, 171 Alexandras avenue, 11522, Athens. PIVAC 23 aims to bring together scientists working on translational and clinical cancer research for three days of presentations on the most recent advances in these fields including (i) immunotherapies (cellular, immune checkpoint blockade, vaccines); (ii) innate immunity and tumor control; (iii) host- tumor interactions in the tumor microenvironment; (iv) in vitro and in vivo models for cancer immunotherapies (v) combinational cancer therapy approaches; and (vi) prognostic and predictive biomarkers in tumors and immune cells. Improved knowledge of genomic and molecular alterations in tumors has significantly contributed to improved clinical outcomes. However, many hurdles remain to be overcome. Alterations in the tumor genome are associated not only with immune stimulation but also with an immune suppressive microenvironment and tumor immune escape mechanisms. Currently, various promising novel approaches are being employed to improve the efficacy of immunotherapies alone or in combination with targeted therapies, often by seeking to reverse the immunosuppressive environment. Additionally, prognostic signatures are being sought in order to provide a basis for tailored immunotherapies. During the meeting there will be plenty of time for fruitful discussions between speakers and participants to encourage the emergence of new collaborations. On behalf of the Organizing Committee, we are pleased to invite you to participate in this Meeting. Chair: Olga Balaoura, President of the Board of Directors and Commander of the Saint Savvas Cancer Hospital Dr. Constantin N. Baxevanis, Scientific Director Cancer Immunology and Immunotherapy Center, Cancer Research Center, Saint Savvas Cancer Hospital George Georgiou, Deputy Director of Finance, Saint Savvas Cancer Hospital Prof. Graham Pawelec, Department of Immunology, University of Tübingen, Tübingen, Germany Head of Conference Secretariat, Dr. Vasiliki Gkioka

Invited speaker at 6th Symposium on Advances in Cancer Immunotherapy, Athens, Greece

2020

Τhe Hellenic Society of Immuno-Oncology organized the “6th Symposium on Advances in Cancer Immunology and Immunotherapy” that was held on December 3-5, 2020 online through a special platform. The main objectives was to gather, share and exchange experiences and ideas, translate and extend this knowledge to the clinic, promote interactions between speakers and participants and encourage stimulating discussions, provide network opportunities and stimulate new collaborations.

Invited Speaker at the 3rd Summer School in Immuno-Oncology, Larissa, Greece, organized by the Hellenic Society of Immuno-Oncology.

2020

Invited speaker at the 5th Symposium on Advances in Cancer Immunology and Immunotherapy, Athens, Greece.

2019

Invited speaker at PIVAC-19 in Athens, Greece

2019

External examiner for MSc Medical Molecular Biology with Genetics and MRes in Molecular Medicine - University of Bangor

2021 - 2025

External Examiner for BSc Biomedical Science - Queen's University Belfast

2021 - 2025

External Assessor for BSc Biomedical Sciences - Aberystwyth University

2019 - 2019

External Examiner to BSc/MSci Biomedical Sciences - Newcastle University

2017 - 2021

Guest Editor of the Special Issue on 'Molecular Mechanisms underlying, and Therapies targeting, Acute Myeloid Leukaemia II' in International Journal of Molecular Sciences

2022 - 2022

Review Editor for Frontiers in Oncology

2022

Guest Editor of the Special Issue on 'Molecular Mechanisms underlying, and Therapies targeting, Acute Myeloid Leukaemia' in International Journal of Molecular Sciences

2021 - 2021

Acute myeloid leukaemia (AML) is the second most frequent haematological malignancy in the paediatric population and remains a leading cause of childhood cancer mortality. In adults AML is rare, increasing in incidence with age, but it is still the most common form of acute leukaemia. Paediatric AML is viewed as a separate disease to adult AML, thought to occur due to single genetic changes that alone are enough to cause AML at a young age. In adults it is thought a lifetime accumulation of genetic alterations leads to the development of disease in later life. In both patient groups, and despite improvements to patient outcomes and associated overall survival (OS) rates they offer, current therapies still have limitations. It is essential, therefore, that we continue to identify new targets for therapy so that we can widen the scope of future treatments and determine their relevance to paediatric and adult leukaemias. This special issue will focus on the identification and characterisation of the molecular mechanisms that underlie AML pathogenesis and new targets for the therapy of this rare and heterogenous disease. The aim is to review the state-of-the-art and look beyond current therapies to see where the future of AML treatment may reside. For more details see https://www.mdpi.com/journal/ijms/special_issues/Molecular_Myeloid

Associate Editor, Journal of Translational Medicine

2020 - 2023

Associate Editor for the ‘Translational Hematology’ section of Journal of Translational Medicine. Role includes assessing manuscripts in the field of Translational Hematology, guiding them through the peer review process and ensuring they adhere to the ethos, editorial standards, policies and scope of the journal. Associate Editors’ are encouraged to take an active interest in journal development and advocacy.

Editor-in-Chief Biomarkers in Cancer

2008 - 2019

Member of the Biochemical Society

2024

Member of the NC3Rs new approach methodologies (NAMs) network

2024

The NAMs Network is a community of researchers, developers and industry and regulatory end-users working together to accelerate the use of new approach methodologies.

Member of the Society for Reproduction and Fertility

2024

Membership of the Society is open to scientists and students worldwide who work on any aspect of reproductive biology or fertility and provides various benefits including bursaries to attend the annual Fertility conference, access to travel grants and sponsorship and online access to Reproduction and reduced personal subscriptions other reproduction and fertility journals and Societies.

European Association for Cancer Research (EACR)

2021

Member of the World Endometriosis Society (WES)

2020

Senior Fellow of the Higher Education Academy (SFHEA)

2019

Member of the Higher Education Academy since 2011 2011 AHEA 2012 FHEA 2019 SFHEA

Fellow of the Royal Society of Biology (FRSB)

2014 - 2022

Fellow of the Higher Education Association (FHEA)

2012 - 2019

Associate of the Higher Education Academy (AHEA)

2011 - 2012

Genetics Society

1990

International Faculty, Progress in Vaccines Against Cancer (PIVAC)

2024

The first “Progress in Vaccination against Cancer” took place in Cambridge, UK, in 2001, at a time when many investigators were highly sceptical as to whether any progress could ever be achieved in this endeavour. However, much has changed in the intervening two decades, during which the small intimate PIVAC conferences have been held annually, missing only one year because of the COVID-19 pandemic lockdown. Hence, PIVAC #23 will be taking place in 2024, September 26–28 in Prague, Czech Republic. It is our pleasure to invite you to present your latest data at this meeting, and to discuss progress in vaccination against cancer in the historic environs of Charles University, one Europe´s oldest. We are looking forward to another excellent PIVAC meeting in the wonderful city of Prague next September, and sincerely we hope that you will be able to join us for this event.

External referee for KWF Kankerbestrijding – Dutch Cancer Society (DCS)

2024

KWF Kankerbestrijding/KWF Dutch Cancer Society was founded in 1949. Back then, the prognosis for cancer patients was bleak: 5 years post-diagnosis, only 49% of the cancer patients was still alive. Nowadays, this number has increased to 68% . We thank our donors, whose generous donations has enabled researchers to detect, understand and treat cancer better. However, despite these promising numbers, our task is not finished. The increasing complexity of oncology is accompanied by new challenges and questions. Not only for patients and doctors, but for society as a whole. If more cancer patients can be cured, or survive longer, how can we optimize their quality of life? How can we stimulate better treatment for rare and hard-to-treat tumours? And how can we prevent cancer? The patient is key Through our actions, we support patients in every aspect of their life. For people who have not yet been diagnosed with cancer, as well as for patients who can’t be cured. Our main goals are: To prevent cancer wherever we can. To stimulate better treatment for every type of cancer. To aim for a better quality of life for (recovered) patients and their loved ones. To ensure that high quality palliative care is available for all patients. Through stimulation of focused scientific research, policy making, knowledge transfer and collaboration with our stakeholders, KWF is dedicated to improving the lives of cancer patients and their loved ones. Our organisational structure enables us to respond quickly to developments in society and research. Examples include our campaign for the HPV-vaccine, which prevents HPV-related cancers. And our support for new initiatives to stimulate broader availability of cancer drugs. There are enormous challenges ahead of us. KWF can’t face these alone. Therefore, we join forces with (inter)national stakeholders to achieve our goals. With the support of society, which includes 100,000 volunteers and almost 1 million donors. We work together for a better life with and without cancer; this is what we stand for! KWF Dutch Cancer Society KWF consists of: A Supervisory Board who supervises the policies of the administration, and the general course of events of KWF. A board who is responsible for the general management of KWF. The board members are Carla van Gils and Dorine Manson. The Supervisory Board consists of the following members: Ir. Wiebe Draijerchair Dr. Bas Leerink Koos Timmermans Drs. Mijke van Ballegooijen Hilde Garssen Michaëla Ulrici KWF Board of Advisors KWF Board of Advisors consists of about 100-120 experts who advise KWF on achieving its mission goals from multiple perspectives. The experts are scientists, (former) patients, volunteers, health care providers and other relevant stakeholders.

Grant Review for Swiss National Science Foundation

2023 - 2023

Evaluation of a grant proposal for the Swiss National Science Foundation (SNSF)

Grant Review - Bart's Charity

2023 - 2023

Grant Review - UKRI

2023 - 2023

Grant Review X 2 - Medical Research Council

2023

Grant review for World Cancer Research Fund International

2022 - 2022

Reviewed a grant for World Cancer Research Fund International

Grant reviewer for Leukaemia UK

2022 - 2022

Grant Reviewer - Cancer Research Trust NZ

2021 - 2021

Grant reviewer for the Cancer Research Trust NZ

Grant Reviewer for the Belgium Foundation Against Cancer

2021

Scientific Expert Reviewer for the Italian Medicines Agency (AIFA)

2020